Aguilar, David D.
Radzik, Leana K.
Schiffino, Felipe L.
Folorunso, Oluwarotimi O.
Zielinski, Mark R.
Coyle, Joseph T.
Balu, Darrick T.
McNally, James M.
Funding for this research was provided by:
National Institute of Mental Health (T32MH016259, F32MH119838)
Stonehill College (SURE Fellowship)
University of Texas Medical Branch at Galveston (Jeane B. Kempner Postdoctoral Fellowship)
McLean Hospital (McLean Presidential Fellowship)
U.S. Department of Veterans Affairs (IBX002823A, IK2BX002130)
Whitehall Foundation (2018-05-107)
BrightFocus Foundation (A2019034S)
National Institute on Aging (1R03AG063201-01)
United States-Israel Binational Science Foundation (2019021)
National Institute of Neurological Disorders and Stroke (R01NS098740-02)
Article History
Received: 5 March 2021
Accepted: 9 April 2021
First Online: 27 April 2021
Competing interests
: All authors except JTC and DTB declare no competing financial interests in relation to the work described. JTC reports holding a patent on D-serine to treat serious mental disorder that is owned by Massachusetts General Hospital but could yield royalties, and a patent on an AI-based EEG method to predict psychotropic drug response. DTB served as a consultant for LifeSci Capital and received research support from Takeda Pharmaceuticals.